Subsequent genomic profiling, utilizing DNA-based cancer panel sequencing (Oncomine Comprehensive Assay Plus), revealed a homozygous deletion of the CDKN2A and MTAP gene locus but did not identify further actionable mutations. The gene discussed is MTAP; the disease is cancer.